Latest research on Pregabalin

Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. [Wikipedia]

Pregabalin dosage

The incidence of these adverse effects increases with larger Pregabalin doses [8, 10]. [source, 2016]
To examine the combination effects of radon and Pregabalin, mice were administered Pregabalin at a dose of 3 mg/kg of body weight immediately after radon inhalation. [source, 2016]
Next, we examined dose- and time-dependent changes in the 50% paw withdrawal threshold following Pregabalin administration. [source, 2016]
In addition, mechanical allodynia was mitigated in a dose-dependent manner at 60 minutes after Pregabalin administration (Figure 2(b)). [source, 2016]
The lipid peroxide level in the paw of mice, which were administrated Pregabalin at a dose of 10 mg/kg of body weight, significantly decreased (Figure 3). [source, 2016]
To our knowledge, there are no reports that low-dose irradiation including radon inhalation has effects similar to Pregabalin as described above or that Pregabalin has antioxidative effects. [source, 2016]
Pregabalin (PGB), another Calcium channel a2δ ligand, has also shown benefit in the treatment of neuropathic pain, although such benefits are related to high doses, which are evidently associated with AE occurrence, including dizziness, somnolence, and peripheral edema[10]. [source, 2016]
Freeman et al. showed, in a meta-analysis, that adverse events related to Pregabalin use are dose-related, dizziness being the most common AE (28%), with 600 mg/d, followed by peripheral edema (16%) and somnolence (13%) [10]. [source, 2016]
The anticonvulsants Pregabalin and Gabapentin, low-dose TCAs, SSNRIs Duloxetine and Venlafaxine, and topical Lidocaine showed efficacy for the management of NP and were recommended as first-line and second-line medications, respectively. [source, 2016]
We tried to increase dosage of drug (Pregabalin 300 mg/day) and add opioids (oxycodon 10 mg/day) but in vain. [source, 2016]